Stay updated with breaking news from Nasdaq dawn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It dedicated to developing and commercializing targeted therapies for patients of all ages […] ....
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) issued its quarterly earnings data on Monday. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01), MarketWatch Earnings reports. Shares of Day One Biopharmaceuticals stock traded up $0.37 during trading on Wednesday, hitting $12.78. The stock had a trading volume of […] ....